Certara Inc (CERT) - Net Assets
Based on the latest financial reports, Certara Inc (CERT) has net assets worth $1.06 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.56 Billion) and total liabilities ($493.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Certara Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.06 Billion |
| % of Total Assets | 68.28% |
| Annual Growth Rate | 11.6% |
| 5-Year Change | 2.01% |
| 10-Year Change | N/A |
| Growth Volatility | 23.69 |
Certara Inc - Net Assets Trend (2018–2025)
This chart illustrates how Certara Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Certara Inc for the complete picture of this company's asset base.
Annual Net Assets for Certara Inc (2018–2025)
The table below shows the annual net assets of Certara Inc from 2018 to 2025. For live valuation and market cap data, see CERT company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.06 Billion | +0.39% |
| 2024-12-31 | $1.06 Billion | +1.13% |
| 2023-12-31 | $1.05 Billion | -3.04% |
| 2022-12-31 | $1.08 Billion | +3.63% |
| 2021-12-31 | $1.04 Billion | +26.73% |
| 2020-12-31 | $822.13 Million | +67.08% |
| 2019-12-31 | $492.05 Million | -0.15% |
| 2018-12-31 | $492.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Certara Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11544400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.64 Million | 0.15% |
| Other Comprehensive Income | $2.04 Million | 0.19% |
| Other Components | $1.19 Billion | 111.87% |
| Total Equity | $1.06 Billion | 100.00% |
Certara Inc Competitors by Market Cap
The table below lists competitors of Certara Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xiamen International Airport Co Ltd
SHG:600897
|
$983.49 Million |
|
Hubei Heyuan Gas Co Ltd
SHE:002971
|
$983.51 Million |
|
Northern Dynasty Minerals Ltd
TO:NDM
|
$983.51 Million |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
$983.61 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
$982.89 Million |
|
Shanghai Aladdin Biochemical Technology Co. Ltd. A
SHG:688179
|
$982.54 Million |
|
Suzhou Xianglou New Material Co. Ltd.
SHE:301160
|
$982.43 Million |
|
Asiana Airline
KO:020560
|
$982.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Certara Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,058,656,000 to 1,062,795,000, a change of 4,139,000 (0.4%).
- Net loss of 1,595,000 reduced equity.
- Share repurchases of 42,610,000 reduced equity.
- Other comprehensive income increased equity by 15,464,000.
- Other factors increased equity by 32,880,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.59 Million | -0.15% |
| Share Repurchases | $42.61 Million | -4.01% |
| Other Comprehensive Income | $15.46 Million | +1.46% |
| Other Changes | $32.88 Million | +3.09% |
| Total Change | $- | 0.39% |
Book Value vs Market Value Analysis
This analysis compares Certara Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.93x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.66x to 0.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $3.72 | $6.18 | x |
| 2019-12-31 | $3.13 | $6.18 | x |
| 2020-12-31 | $5.37 | $6.18 | x |
| 2021-12-31 | $6.95 | $6.18 | x |
| 2022-12-31 | $6.78 | $6.18 | x |
| 2023-12-31 | $6.59 | $6.18 | x |
| 2024-12-31 | $6.60 | $6.18 | x |
| 2025-12-31 | $6.63 | $6.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Certara Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.38%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.46x
- Recent ROE (-0.15%) is above the historical average (-2.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -6.75% | -20.31% | 0.16x | 2.13x | $-82.53 Million |
| 2019 | -1.81% | -4.28% | 0.20x | 2.11x | $-58.13 Million |
| 2020 | -6.01% | -20.28% | 0.19x | 1.54x | $-131.61 Million |
| 2021 | -1.27% | -4.64% | 0.19x | 1.45x | $-117.45 Million |
| 2022 | 1.36% | 4.39% | 0.21x | 1.46x | $-93.24 Million |
| 2023 | -5.29% | -15.62% | 0.23x | 1.49x | $-160.04 Million |
| 2024 | -1.14% | -3.13% | 0.24x | 1.49x | $-117.92 Million |
| 2025 | -0.15% | -0.38% | 0.27x | 1.46x | $-107.87 Million |
Industry Comparison
This section compares Certara Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $349,146,170
- Average return on equity (ROE) among peers: -178.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Certara Inc (CERT) | $1.06 Billion | -6.75% | 0.46x | $983.48 Million |
| Aclarion Inc (ACON) | $2.23 Million | -317.55% | 0.31x | $1.99 Million |
| American Well Corp (AMWL) | $480.19 Million | -140.60% | 0.23x | $90.87 Million |
| Heartbeam Inc (BEAT) | $-26.87 Million | 0.00% | 0.00x | $30.37 Million |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $-3.06 Million | 0.00% | 0.00x | $6.51 Million |
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $612.55 Million | -25.24% | 8.03x | $8.82 Billion |
| Carlsmed, Inc. Common Stock (CARL) | $-70.63 Million | 0.00% | 0.00x | $253.42 Million |
| CareCloud Inc. (CCLD) | $101.25 Million | -8.70% | 0.36x | $117.28 Million |
| CareMax Inc (CMAX) | $61.44 Million | -1112.15% | 9.14x | $381.50 |
| Claritev Corporation (CTEV) | $1.99 Billion | 0.49% | 3.21x | $277.75 Million |
About Certara Inc
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pha… Read more